CN106727486A - 治疗或预防疲劳的方法 - Google Patents

治疗或预防疲劳的方法 Download PDF

Info

Publication number
CN106727486A
CN106727486A CN201710080968.3A CN201710080968A CN106727486A CN 106727486 A CN106727486 A CN 106727486A CN 201710080968 A CN201710080968 A CN 201710080968A CN 106727486 A CN106727486 A CN 106727486A
Authority
CN
China
Prior art keywords
compound
purposes
fatigue
sleep
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710080968.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·A·哈耶拉拉
G·布里姆
S·E·巴兹
S·M·梅尔尼克
D·泰勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of CN106727486A publication Critical patent/CN106727486A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201710080968.3A 2009-06-22 2010-06-21 治疗或预防疲劳的方法 Pending CN106727486A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21908209P 2009-06-22 2009-06-22
US61/219,082 2009-06-22
CN2010800277527A CN102481274A (zh) 2009-06-22 2010-06-21 治疗或预防疲劳的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2010800277527A Division CN102481274A (zh) 2009-06-22 2010-06-21 治疗或预防疲劳的方法

Publications (1)

Publication Number Publication Date
CN106727486A true CN106727486A (zh) 2017-05-31

Family

ID=43429751

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710080968.3A Pending CN106727486A (zh) 2009-06-22 2010-06-21 治疗或预防疲劳的方法
CN2010800277527A Pending CN102481274A (zh) 2009-06-22 2010-06-21 治疗或预防疲劳的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010800277527A Pending CN102481274A (zh) 2009-06-22 2010-06-21 治疗或预防疲劳的方法

Country Status (13)

Country Link
US (5) US8741950B2 (enExample)
EP (1) EP2445490B1 (enExample)
JP (3) JP6095366B2 (enExample)
KR (3) KR102021075B1 (enExample)
CN (2) CN106727486A (enExample)
AU (1) AU2010270971B2 (enExample)
BR (1) BRPI1015233A2 (enExample)
CA (1) CA2765463C (enExample)
IN (1) IN2012DN00624A (enExample)
MX (1) MX2012000034A (enExample)
RU (1) RU2567801C2 (enExample)
TW (1) TWI453014B (enExample)
WO (1) WO2011005473A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2435403T3 (es) 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia
US8741950B2 (en) 2009-06-22 2014-06-03 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
KR101783633B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 섬유근육통 증후군의 치료 방법
EP2496228B1 (en) 2009-11-06 2014-01-15 SK Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9060994B2 (en) 2011-12-21 2015-06-23 Inno Biosciences, S.p.A. Combination therapy with interferon and andrographolides for Multiple Sclerosis
RU2689984C2 (ru) * 2013-03-13 2019-05-30 ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи Лечение катаплексии
KR20160030955A (ko) * 2013-07-12 2016-03-21 에스케이바이오팜 주식회사 금연의 촉진
EP3021838B1 (en) 2013-07-18 2020-05-27 Jazz Pharmaceuticals Ireland Limited Treatment for obesity
CN115350236A (zh) * 2013-11-08 2022-11-18 传世医疗(瑞士)有限公司 用于管理癌症和治疗癌症并存病的方法
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI698415B (zh) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
WO2018048871A1 (en) 2016-09-06 2018-03-15 Jazz Pharmaceuticals International Iii Limited Solvate form of (r)-2-amino-3-phenylpropyl carbamate
CA3039045A1 (en) 2016-10-06 2018-04-12 Jazz Pharmaceuticals International Iii Limited Carbamoyl phenylalaninol compounds and uses thereof
WO2018124769A1 (ko) * 2016-12-30 2018-07-05 주식회사 동진쎄미켐 코팅 조성물 및 이로부터 제조되는 필름
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
CN111094238B (zh) 2017-07-31 2023-06-09 杰资制药爱尔兰有限公司 氨基甲酰基苯丙氨醇类似物及其用途
JP7428480B2 (ja) * 2019-06-06 2024-02-06 雪印メグミルク株式会社 睡眠改善用組成物及び組成物を含む食品、医薬品、飼料
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
AU2022390879A1 (en) * 2021-11-16 2024-06-13 Axsome Malta Ltd. Methods and compositions for treating cognitive impairment
CN121620365A (zh) 2023-06-29 2026-03-06 艾克萨姆治疗股份有限公司 向哺乳期妇女施用索安非托的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1135209A (zh) * 1994-09-09 1996-11-06 株式会社油公 新的氨基甲酸苯基烷基氨基醇酯及其制备方法
CN1204316A (zh) * 1996-10-10 1999-01-06 Sk株式会社 O－氨基甲酰基-苯丙胺醇化合物、其药学上有用的盐和它们的制备方法
CN101217949A (zh) * 2005-06-08 2008-07-09 Sk株式会社 治疗睡眠-清醒病症

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
KR0173862B1 (ko) * 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) * 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
AU4567597A (en) 1996-10-08 1998-05-05 Institute Of Child Health Mutant ciita molecule and uses thereof
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US20040229951A1 (en) 2003-05-15 2004-11-18 Arthur Vanmoor Method of treating fatigue by enhancing the effectiveness of the human immune system
RU2267319C2 (ru) * 2003-07-15 2006-01-10 Общество с ограниченной ответственностью "Интер-Кэр" Фармацевтическая композиция и способ лечения синдрома хронической усталости с ее использованием
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
RU2007119648A (ru) * 2004-10-28 2008-12-10 СК Холдингз Ко. Способ лечения депрессии
US8552060B2 (en) 2005-06-22 2013-10-08 Sk Biopharmaceuticals Co., Ltd. Methods for treatment of sexual dysfunction
CA2616721C (en) 2005-07-26 2014-01-21 Janssen Pharmaceutica N.V. Methods for treating substance-related disorders
CN101557804A (zh) 2006-10-13 2009-10-14 詹森药业有限公司 氨基甲酸苯基烷基氨基酯组合物
US8741950B2 (en) * 2009-06-22 2014-06-03 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
EP2496228B1 (en) 2009-11-06 2014-01-15 SK Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
KR101783633B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 섬유근육통 증후군의 치료 방법
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
RU2689984C2 (ru) * 2013-03-13 2019-05-30 ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи Лечение катаплексии
JP6215740B2 (ja) * 2014-03-14 2017-10-18 本田技研工業株式会社 部品の締結構造

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1135209A (zh) * 1994-09-09 1996-11-06 株式会社油公 新的氨基甲酸苯基烷基氨基醇酯及其制备方法
CN1204316A (zh) * 1996-10-10 1999-01-06 Sk株式会社 O－氨基甲酰基-苯丙胺醇化合物、其药学上有用的盐和它们的制备方法
CN101217949A (zh) * 2005-06-08 2008-07-09 Sk株式会社 治疗睡眠-清醒病症

Also Published As

Publication number Publication date
EP2445490B1 (en) 2023-02-08
WO2011005473A2 (en) 2011-01-13
MX2012000034A (es) 2012-02-21
US8741950B2 (en) 2014-06-03
JP2018188450A (ja) 2018-11-29
JP6095366B2 (ja) 2017-03-15
US9999609B2 (en) 2018-06-19
TWI453014B (zh) 2014-09-21
TW201105320A (en) 2011-02-16
IN2012DN00624A (enExample) 2015-06-12
KR102021075B1 (ko) 2019-11-04
KR20170086710A (ko) 2017-07-26
BRPI1015233A2 (pt) 2018-02-20
CA2765463A1 (en) 2011-01-13
US10507192B2 (en) 2019-12-17
EP2445490A2 (en) 2012-05-02
CN102481274A (zh) 2012-05-30
KR20190105675A (ko) 2019-09-17
CA2765463C (en) 2018-10-09
US20120142769A1 (en) 2012-06-07
EP2445490A4 (en) 2019-10-23
WO2011005473A9 (en) 2011-05-12
US9464041B2 (en) 2016-10-11
US20140243406A1 (en) 2014-08-28
US20200061017A1 (en) 2020-02-27
JP2012530779A (ja) 2012-12-06
KR102173587B1 (ko) 2020-11-04
JP2015214564A (ja) 2015-12-03
AU2010270971B2 (en) 2015-08-20
RU2012101947A (ru) 2013-07-27
US20180263950A1 (en) 2018-09-20
RU2567801C2 (ru) 2015-11-10
KR20120098578A (ko) 2012-09-05
US20170000756A1 (en) 2017-01-05
JP6368285B2 (ja) 2018-08-01
AU2010270971A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
CN106727486A (zh) 治疗或预防疲劳的方法
CA2765463E (en) Methods for treating or preventing fatigue
KR101483802B1 (ko) 외투층 세포 림프종의 치료에 있어서 3-(4-아미노-1-옥소-1,3-디히드로-이소인돌-2-일)-피페리딘-2,6-디온의 용도
DE60118571T2 (de) Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten
JP6562907B2 (ja) （ｓ）−３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの製剤
KR20070099031A (ko) 4-아미노-2-(3-메틸-2,6-디옥소피페리딘-3-일)-이소인돌-1,3-디온을 사용한 방법 및 조성물
JP6339251B2 (ja) シクロプロパンカルボン酸｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシ−フェニル）−２−メタンスルホニル−エチル］−３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−イル｝−アミドの製剤
AU2019208238A1 (en) Therapeutic Modifiers of the Reverse Mode of ATP Synthase
CA3050553A1 (en) Therapeutic modifiers of the reverse mode of atp synthase
JP6132773B2 (ja) Ｐｄｅ４及び／又はサイトカインの阻害剤としてのフェネチルスルホンイソインドリン誘導体
JP2015535291A (ja) 腎臓に障害のある対象におけるポマリドミドを用いる癌の治療
JP5760008B2 (ja) （メチルスルホニル）エチルベンゼンイソインドリン誘導体及びその治療的使用
US20220125844A1 (en) Opioid antagonists for use in patients using chimeric antigen receptor t and natural killer (nk) cell therapy
HK1234314A1 (en) Methods for treating or preventing fatigue
HK1171657A (en) Methods for treating or preventing fatigue

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1234314

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170531

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1234314

Country of ref document: HK